Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195297 | 0.77 | ALDH1A1 (0.48) | SLC2A1KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4203272 | 0.75 | SLC2A1 (0.48) | SLC2A1KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25074358 | 0.74 | SLC2A1 (1.00) | SLC2A1 | |
| SCHEMBL30252153 | 0.74 | SLC2A1 (1.00) | SLC2A1 | |
| SCHEMBL3507524 | 0.72 | SLC2A1 (0.54) | SLC2A1KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31661504 | 0.72 | SLC2A1 (0.54) | SLC2A1KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3742531 | 0.71 | KDM4E (0.55) | SLC2A1CYP1A2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL8685682 | 0.70 | SLC2A1 (0.52) | SLC2A1KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11225244 | 0.70 | CDK4 (0.53) | SLC2A1KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29928879 | 0.70 | CDK4 (0.53) | SLC2A1KCNH2CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| CN-101365695-A | Quinazoline derivatives as anticancer agents | ASTRAZENECA AB (SE) | 2009-02-11 | — | — | CN | disclosed |
| EP-1940825-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034143-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ABL1, ERBB2, CDK2 | SLC2A1 1417/4885KCNH2 3976/4885CYP1A2 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.